Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan

Aerie Pharmaceuticals announced the appointment of Scott Laranjo as Director, Marketing, Roclatan, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed dose combination of Aerie product Rhopressa, and widely prescribed PGA latanoprost. The Roclatan new drug application (NDA) submission to the FDA is expected to take place in the second quarter of 2018. Mr. Laranjo previously held related marketing positions at UCB, Inc. and Allergan, Inc.

In connection with his acceptance of the position as Director, Marketing, Roclatan, Mr. Laranjo will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.